v3.25.1
Acquisitions and Other Transactions (Narrative) (Details)
$ in Millions
3 Months Ended
Mar. 15, 2024
USD ($)
Mar. 31, 2025
USD ($)
Mar. 31, 2024
USD ($)
Feb. 25, 2025
USD ($)
Dec. 31, 2024
USD ($)
Business Combination [Line Items]          
Contingent consideration   $ 412.2     $ 556.1
Goodwill   6,462.1     9,133.3
Measurement Input, Discount Rate          
Business Combination [Line Items]          
Business Combination, Fair Value, In Process Research And Development, Measurement Input 0.20        
Idorsia Pharmaceuticals Ltd.          
Business Combination [Line Items]          
Business Combination, Price of Acquisition, Expected $ 350.0        
Business Combination, Contingent Consideration, Liability, Milestone Payment Payable Upon Development And Regulatory Milestones 300.0     $ 200.0  
Business Combination, Contingent Consideration, Liability, Milestone Payment Payable Upon Achievement Of Tiered Sales Milestones 2,100.0        
Business Combination, Acquisition-Related Cost, Expense   2.6 $ 0.3    
Payments to Acquire Businesses, Net of Cash Acquired 695.0        
Contingent consideration 345.0 $ 270.0     $ 378.0
Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, In Process Research And Development 675.0        
Business Combination, Contingent Consideration, Liability, Milestone Payment       250.0  
Business Combination, Recognized Liability Assumed, Other Liability, Current       $ 100.0  
Goodwill $ 19.5